Hepatitis C: Pan-Genotypic DAA Regimens, Treatment Simplification, and Cure Rates
Pan-Genotypic Regimens: Sofosbuvir/Velpatasvir and Glecaprevir/Pibrentasvir
Two pan-genotypic regimens dominate HCV treatment. Sofosbuvir/velpatasvir (Epclusa, 400/100 mg daily for 12 weeks) achieved SVR12 rates of 99% in genotype 1, 100% in genotype 2, 95% in genotype 3, and 99-100% in genotypes 4-6 in the ASTRAL trials. Glecaprevir/pibrentasvir (Mavyret, 300/120 mg daily for 8 weeks in non-cirrhotic treatment-naive patients) demonstrated SVR12 of 97-100% across all genotypes in the ENDURANCE and EXPEDITION trials. The shorter 8-week course of glecaprevir/pibrentasvir offers practical advantages for treatment-naive non-cirrhotic patients.
Simplified Treatment Algorithm
The AASLD-IDSA simplified treatment algorithm allows initiation without genotype testing, liver biopsy, or specialist consultation for treatment-naive adults without known cirrhosis, hepatitis B coinfection, prior HCV treatment, or current pregnancy. Under the simplified approach, either pan-genotypic regimen can be prescribed by primary care providers after confirming HCV RNA positivity, checking baseline renal function, and reviewing drug-drug interactions. This approach supports HCV elimination goals by reducing barriers to treatment in primary care and community health settings.
Special Populations: Cirrhosis and Renal Impairment
For compensated cirrhosis (Child-Pugh A), sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 12 weeks (extended from 8) are recommended. Decompensated cirrhosis (Child-Pugh B/C) requires a protease inhibitor-free regimen: sofosbuvir/velpatasvir for 12 weeks, often with ribavirin weight-based dosing (1000-1200 mg daily) to optimize SVR. Glecaprevir/pibrentasvir is contraindicated in decompensated cirrhosis due to hepatic clearance of protease inhibitors. For patients with eGFR <30 mL/min, glecaprevir/pibrentasvir is preferred as it is renally safe, while sofosbuvir-based regimens carry theoretical nephrotoxicity concerns (though real-world data show acceptable safety at reduced eGFR).
Sponsored
Treatment Failure and Retreatment
DAA failure occurs in fewer than 5% of treatment-naive patients. For patients who fail a first-line regimen, sofosbuvir/velpatasvir/voxilaprevir (Vosevi, 12 weeks) is the recommended salvage regimen, achieving SVR12 of 91-100% in DAA-experienced patients across the POLARIS trials. NS5A resistance-associated substitutions (RAS), particularly Y93H, are the primary driver of virologic failure and should be tested before retreatment. For genotype 3 patients with NS5A RAS and cirrhosis, extending sofosbuvir/velpatasvir/voxilaprevir to 24 weeks or adding ribavirin may be considered.
Post-SVR Monitoring and HCC Surveillance
SVR12 is considered a virologic cure with a relapse rate below 1% beyond 12 weeks. However, HCV cure does not eliminate liver-related risk in patients with advanced fibrosis (F3) or cirrhosis, who require ongoing hepatocellular carcinoma surveillance with abdominal ultrasound every 6 months indefinitely. The incidence of HCC after SVR in cirrhotics is approximately 1-2% per year, lower than untreated cirrhotics (2-8% per year) but not zero. Patients who achieve SVR should be counseled about reinfection risk if ongoing exposure persists, with annual HCV RNA testing recommended for persons who inject drugs.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.